Intensified Immunochemotherapy with Autologous Stem Cell Transplantation for Mantle Cell Lymphoma - Could It Still be Considered the Standard of Care? [PDF]
Liliana Tušková +8 more
openalex +1 more source
Evolution of conditioning regimens prior to autologous stem cell transplantation in lymphoma patients. [PDF]
Tian H, Wang R, Cong D, Bai Y, Zhang W.
europepmc +1 more source
Abstract Purpose Treating large cartilage lesions in the knee remains a challenge. While matrix‐associated autologous chondrocyte implantation (MACI) is the gold standard for medium to large lesions, the minced cartilage technique has shown promise in smaller defects. Enhancing this technique with biomaterials has been suggested for larger lesions, but
Johanna Mayr +5 more
wiley +1 more source
High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry [PDF]
Eisei Kondo +15 more
openalex +1 more source
The Efficacy of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Ewing Sarcoma Patients. [PDF]
Kuzu ÖF +9 more
europepmc +1 more source
Autologous-Autologous Tandem Hematopoietic Stem Cell Transplantation [PDF]
openaire +1 more source
Abstract Purpose To evaluate the safety and efficacy of intra‐articular autologous transplantation of adipose‐derived connective tissue micrografts rich in stromal vascular fraction (CTM‐SVF), obtained using an enzyme‐free system (Hy‐Tissue® SVF) for knee osteoarthritis (OA). Methods Thirty patients (mean age of 53.3 ± 6.4 years) with Kellgren–Lawrence
Laura Mangiavini +11 more
wiley +1 more source
Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome. [PDF]
Le M +5 more
europepmc +1 more source
Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley +1 more source

